Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy

Exclusion Criteria

• •Women with stage 4 breast cancer (presence of distant metastases)
• •Women with normal bone density by DXA (T-score \> -1.0 SD)bone density by DXA, except in the instance of a fragility fracture.
• •Women with history of any illness known to affect bone and mineral metabolism, such as renal failure (estimated GFR \<30), hepatic failure, malignancy (excluding breast cancer, treated superficial basal and squamous cell carcinoma and malignancies where the diagnosis itself or its treatment would not adversely affect bone metabolism), untreated primary hyperparathyroidism, and malabsorption.
• •Women being treated with oral glucocorticoid therapy \>3 months for suppression therapy, and certain anti-seizure medications which may adversely affect bone metabolism (phenobarbital, phenytoin, carbamazepine).
• •Those with untreated active peptic ulcer disease
• •Those with osteoporosis by BMD (T-score -2.5 SD at the spine or total hip) or a history of fragility fracture as an adult. However, as discussed above, osteoporotic women may elect to enroll in the study.
• •Women treated with oral bisphosphonates or calcitonin for 3 months within the last year (3 month washout period)
• •Men and children will be excluded because they do not get postmenopausal osteoporosis following treatment with an aromatase inhibitor
• •Women with very poor dental hygiene (as assessed by the baseline dental exam) in need of dental extraction during the study
• •Use of fluoride for more than 1 month ever (except for dental treatment)
• •Less than 2 evaluable vertebrae
• •Distant metastatic disease